Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces its sales for the 4th quarter and full year to 31 December 2015.

Ludovic Lastennet, CEO of Implanet, says: “Our annual performance shows buoyant sales growth in Spine, thanks to market share gains in pediatric scoliosis and our focus on the broader adult degenerative spine market, in which we are planning to launch a number of new products this year. Our 2016 prospects are excellent, we are confident in continued growth across all territories and the accelerated adoption of our technology by surgeons.”

Sales (in € thousands - IFRS)   2015   2014   Change
1st quarter sales   1,599   2,047   -22%
2nd quarter sales   1,707   1,954   -13%
3rd quarter sales   1,693   1,188   +42%
Spine (JAZZ)   561   658   -15%
Knee + Arthroscopy   1,093   1,190   -8%
Hip   -   -   -
Total 4th quarter sales   1,654   1,848   -10%
Spine (JAZZ)   2,806   1,930   +45%
Knee + Arthroscopy   3,847   4,343   -11%
Hip   -   765   -
2015 annual sales   6,653   7,038   -5%
2015 annual sales excluding Hip   6,653   6,273   +6%

Q4 2015 was affected by a very strong base effect in Spine in the United States

Our performance in Spine activity was +78%, +54% and +101% over the first three quarters of the year. The 4th quarter was down compared with the same period of the previous year, a result of major inventory orders by several United States distributors at the end of 2014. Nevertheless, the number of JAZZ surgical procedures was up +56% compared with Q4 2014.

Following an exceptional order for JAZZ implants in the United States in Q4 2014, Implanet recorded a -10% decrease in its global performance in Q4 2015 to €1,654 thousand (vs. €1,848 thousand).

In terms of sequential quarterly growth, Spine activity continued to increase its share of the product mix, and accounted for 51% of total sales. Quarterly sales from this activity are continuing to grow at a pace that is in line with the Company’s forecasts. Spine activity is continuing to record a strong upward trend in France and in the Rest of the world, with growth of +34% to €219 thousand (vs. €163 thousand) and +129% to €153 thousand (vs. €67 thousand) respectively.

2015 was a year of confirmation for JAZZ, driven by growth of +45%

For the full year 2015, Implanet recorded sales of €6,653 thousand, a slight decrease of -5% compared with the 2014 figure of €7,038 thousand, which included €765 thousand in residual 2014 Hip sales. Excluding this Hip activity, growth was +6% compared with the adjusted 2014 sales figure of €6,273 thousand.

While the overall performance was affected by a -11% decrease in Knee activity to €3,847 thousand (compared with €4,343 thousand) in a highly-competitive environment, the 2015 performance was bolstered by the record level of Spine sales, which were up +45% to €2,806 thousand (vs. €1,930 thousand in 2014). Spine activity accounted for 42% of the Group’s total 2015 sales, vs. 27% in 2014. This impressive increase in Spine sales was realized by a strong performance recorded by the various distribution channels across all the Group’s markets: +47% to €952 thousand in the United States, +47% to €1,203 thousand (vs. €821 thousand) in France and +41% to €651 thousand (vs. €461 thousand) in the Rest of the world.

Over the year to 31 December 2015, Implanet sold 843 JAZZ implants in the United States, 2,543 in France and 2,224 in the Rest of the world, giving a total of 5,601 implants and growth by volume of +31% (vs. 4,260 implants over the year to 31 December 2014).

Previous press releases:

  • USA: FDA 510(k) clearance to use the JAZZ platform for all posterior fixation systems
  • BRAZIL: regulatory approval granted by ANVISA to market the JAZZ platform

Next financial press release: 2015 annual results, on 30 March 2016 (after market).

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.